Healthcare’s most compelling growth stories often begin with an unglamorous proposition: make an existing problem less difficult to manage. For INOVIO Pharmaceuticals (NASDAQ: INO), that means a newly approved immunotherapy intended to reduce repeated surgeries. For IDEXX Laboratories (NASDAQ: IDXX), it means helping veterinary practices diagnose disease while building a larger stream of recurring revenue. For Modular Medical (NASDAQ: MODD), it means simplifying insulin delivery while advancing preparations for a potential European expansion. Recent developments give each company a distinct reason to command attention. The common thread is execution. These are three very different businesses, but each offers a version of the same bullish proposition: innovation becomes more valuable when it moves closer to routine commercial use. Wall Street appreciates a promising laboratory. It generally prefers one with a shipping department.
INOVIO Stock: VOCERYQ Approval Opens a New Commercial Chapter
INOVIO Pharmaceuticals (NASDAQ: INO) announced on October 30 that the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, previously known as INO-3107, to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis, or RRP. The treatment is administered with the company’s CELLECTRA 5PSP delivery device. RRP is a rare disease, primarily associated with HPV-6 and HPV-11, in which recurring growths in the respiratory tract can impair speech and obstruct breathing. Surgery removes the growths, but their return can leave patients facing repeated procedures. VOCERYQ is designed to generate an immune response against the underlying HPV targets rather than simply remove the visible consequences. For many following INOVIO, the significance is straightforward. The company now has an approved product around which to build a commercial business, rather than an application awaiting a regulatory decision.
From Development Milestones to Product Launch
The approval follows a documented sequence of development and regulatory work. An August 2025 SEC-filed update reported completion of design-verification testing for CELLECTRA 5PSP and a request to begin a rolling biologics license application submission. INOVIO’s subsequent quarterly filing reported completion of that submission in November 2025. A March 2026 SEC-filed update then confirmed FDA acceptance for review, with an October 30, 2026 target decision date. That chronology matters because it shows the latest announcement emerging from a series of completed steps, not an isolated burst of optimism. INOVIO expects VOCERYQ to become available to order and ship approximately 60 days after the approval announcement, with full commercial field deployment anticipated in the first quarter of 2027. The company has engaged commercial support for recruiting and deploying its medical and field teams. The next chapter therefore has a more tangible vocabulary: physician engagement, patient identification, reimbursement and treatment adoption.
The Clinical Result Behind the Opportunity
The approval announcement described a 32-patient study, with 26 patients included in the efficacy evaluation. Those 26 had undergone at least three surgical papilloma excisions during the preceding year. Seven, or 27%, required no surgical excision during the 12 months after treatment. That result should be read precisely. VOCERYQ is approved to reduce surgery frequency, not as a guaranteed cure. Treatment also follows an initial standard-of-care surgical debulking procedure. Continued approval may depend on confirmation of clinical benefit, and INOVIO must submit a draft confirmatory-study protocol by the end of 2026, with final protocol alignment expected by mid-2027.Even with those qualifications, the commercial logic is attractive. A therapy that can reduce the burden of repeated airway surgery addresses a problem patients and specialists already understand. INOVIO estimates that at least 25,000 people in the United States have RRP, based on its claims-data analysis. That company estimate is not equivalent to an immediately treatable adult market or a revenue forecast, but it provides context for the opportunity. The bullish case rests on converting regulatory progress into meaningful clinical adoption. Approval has opened the door. Commercial execution must now persuade the market that the company can walk through it.
IDEXX Stock: Recurring Diagnostics Revenue Gives Growth Staying Power
IDEXX Laboratories (NASDAQ: IDXX) supplies the established earnings engine in this three-company story. On November 2, IDEXX reported third-quarter 2026 revenue of approximately $1.214 billion, up 10% both as reported and organically. Diluted earnings per share increased 18% to $4.01, while operating margin expanded by one percentage point to 33.1%. Companion Animal Group diagnostics recurring revenue rose 11%, both as reported and organically. The combination is important: higher revenue, faster earnings growth and expanding quarterly profitability. There is a certain elegance to a business whose customers keep ordering the products needed to use the equipment they already own. It is less theatrical than a breakthrough announcement, but the income statement rarely complains.
Why the Installed Base Matters
IDEXX’s 2025 Form 10-K explains the business model clearly. Instrument sales are generally nonrecurring, while associated consumables, rapid-assay kits, reference-laboratory services and certain maintenance offerings generate repeat purchases. Recurring diagnostic revenue represented approximately 79% of consolidated revenue in 2025. The company’s September 2025 quarterly filing had already identified higher consumables and reference-laboratory volumes as contributors to recurring diagnostic revenue growth. The latest results extend that operating narrative. During the third quarter of 2026, IDEXX placed more than 1,900 inVue Dx analyzers, bringing that product’s installed base to nearly 11,000 instruments. VetLab consumables revenue increased 14% as reported and 15% organically, supported by customer additions, greater utilization, pricing and an expanded global premium instrument base. This is the central bullish relationship: more instruments can create more opportunities for repeat testing revenue, while higher utilization can increase the value of instruments already installed. Equipment placement is therefore more than a quarterly sales statistic. It can help establish the infrastructure for future recurring demand.
Higher Guidance Adds Substance to the Story
IDEXX raised its 2026 revenue outlook to $4.741 billion through $4.767 billion, increasing the midpoint by $32 million. It also lifted its diluted EPS outlook to $14.96 through $15.16, a $0.25 improvement at the midpoint. The updated revenue outlook includes approximately $5 million associated with the CoVet acquisition. CoVet adds an artificial-intelligence clinical assistant intended to support veterinary productivity and diagnostics utilization. Alongside inVue Dx and the expansion of Cancer Dx into a multi-cancer panel, the acquisition broadens the company’s effort to make its offerings more useful inside veterinary workflows. The positive interpretation does not require pretending every metric improved. IDEXX lowered its full-year operating-margin outlook to 32.1% through 32.3%, reflecting acquisition-related impacts, even as it raised revenue and earnings expectations. Capital-instrument revenue was also flat during the quarter. That distinction strengthens rather than weakens the analysis. The latest quarter’s appeal rests on recurring revenue growth, utilization and earnings delivery, not on an assumption that every business line must accelerate simultaneously.
Modular Medical Stock: Pivot Advances Toward a Broader Commercial Footprint
Modular Medical (NASDAQ: MODD) offers a smaller, earlier-stage commercial opportunity centered on its Pivot tubeless insulin patch pump. On October 27, the company announced a positive notified-body decision regarding ISO 13485:2016 certification of its quality-management system. Management described the development as another step toward a targeted CE-mark submission in calendar 2027. The distinction is essential: a positive quality-system certification decision is not a CE mark and does not authorize European product sales. Further regulatory review and other applicable requirements remain. Nevertheless, it is a relevant building block. Medical-device expansion depends not only on what a product does, but also on the systems supporting its manufacture and quality. Regulatory housekeeping rarely receives a standing ovation. In medical technology, however, it can determine whether the doors open at all.
A Pump Strategy Built Around Simplicity
Modular Medical’s earlier SEC filings show how the product strategy evolved. Its fiscal 2025 annual report described plans for Pivot as a tubeless update to its initial pump platform. The fiscal 2026 annual report subsequently stated that Pivot received FDA clearance in April 2026 and that initial U.S. shipments began in June. The June 2026 quarterly filing describes a strategy aimed at reducing the cost, complexity and training burdens associated with insulin-pump adoption. The company seeks to reach beyond highly motivated technology users and broaden access among people requiring intensive insulin therapy. That positioning gives the bullish thesis a practical center. Modular Medical does not need to argue that diabetes management requires more complexity. It is attempting to make advanced delivery technology easier to adopt. If that approach gains traction, usability could become a commercial advantage. But product positioning remains a proposition to prove through adoption, manufacturing performance and sustainable economics.
The Opportunity Comes With a Financing Test
Modular Medical’s early commercial status also requires financial perspective. At June 30, 2026, the company reported approximately $3.92 million in cash and cash equivalents, a quarterly net loss of approximately $6.49 million and operating cash usage of approximately $5.97 million. Its quarterly filing stated that conditions raised substantial doubt about its ability to continue as a going concern and that additional capital would be necessary to support operations. Those figures describe the June reporting date, not a verified November cash balance. For many assessing MODD, funding is therefore part of the commercial thesis, not a footnote. The constructive view is that FDA clearance, initial shipments and quality-system progress have created more concrete milestones against which to judge the business. The corresponding challenge is financing the transition without allowing capital needs to overwhelm the value created by product progress.
Three Different Paths to Healthcare Growth
These companies should not be mistaken for interchangeable healthcare bets.
- INOVIO Pharmaceuticals (NASDAQ: INO) offers a newly approved immunotherapy and an approaching commercial launch. The next test is treatment adoption, supported by reimbursement execution and continued clinical obligations.
- IDEXX Laboratories (NASDAQ: IDXX) offers an established recurring-revenue model, growing diagnostic utilization and higher earnings guidance. The next test is sustaining that performance while integrating new capabilities.
- Modular Medical (NASDAQ: MODD) offers an emerging insulin-delivery business with U.S. commercialization underway and a potential European regulatory pathway ahead. The next test combines adoption, manufacturing execution and access to capital.
The attraction is not that all three carry the same risk. They plainly do not. It is that each now has identifiable milestones capable of making its business case more measurable. For many seeking healthcare growth, that is a useful place to begin: an approved treatment approaching launch, a diagnostics franchise producing stronger earnings, and an insulin-pump developer assembling the operational pieces for expansion.The strongest bullish stories do not dispense with hard questions. They give the market better reasons to ask them.
The Sources
- INOVIO Pharmaceuticals, October 30, 2026 announcement of FDA accelerated approval for VOCERYQ.ir.inovio
- INOVIO Pharmaceuticals, SEC-filed second-quarter 2025 business update covering CELLECTRA design-verification testing and rolling-submission preparations.sec
- INOVIO Pharmaceuticals, Form 10-Q for the quarter ended September 30, 2025, including the completed biologics license application submission.sec
- INOVIO Pharmaceuticals, SEC-filed March 12, 2026 update confirming FDA application acceptance and the target decision date.sec
- IDEXX Laboratories, November 2, 2026 third-quarter earnings release and updated full-year outlook.ir.idexx
- IDEXX Laboratories, Form 10-K for the year ended December 31, 2025, including its recurring diagnostic revenue model. sec
- IDEXX Laboratories, Form 10-Q for the quarter ended September 30, 2025, including diagnostic revenue trends.sec
- Modular Medical, October 27, 2026 company announcement regarding the positive notified-body decision on ISO 13485:2016 certification.finance.yahoo
- Modular Medical, Form 10-K for the fiscal year ended March 31, 2025, describing development plans for Pivot.sec
- Modular Medical, Form 10-K for the fiscal year ended March 31, 2026, covering Pivot FDA clearance and initial commercialization.sec
- Modular Medical, Form 10-Q for the quarter ended June 30, 2026, including commercial strategy, liquidity and financing requirements.sec
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
